{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:37:34Z","timestamp":1767339454525},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T00:00:00Z","timestamp":1130371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Besides the autoantibodies included in the diagnostic criteria of type 1 autoimmune hepatitis, many other autoantibodies have been described in this condition. Recently, antibodies against cyclic citrullinated peptide have been validated as specific diagnostic and prognostic markers of rheumatoid arthritis.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To assess whether these antibodies are part of the autoantibody repertoire of type 1 autoimmune hepatitis and correlate with rheumatological manifestations.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Antibodies against cyclic citrullinated peptide were tested by a commercially available enzyme\u2010linked immunosorbent assay.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002The antibodies were found in 12 of 133 (9%) type 1 autoimmune hepatitis, two of 49 (4%) with primary biliary cirrhosis, one of 80 (1%) with hepatitis C virus\u2010related chronic liver disease and 53 of 89 (60%) with rheumatoid arthritis serum samples. High titres were found only in rheumatoid arthritis and type 1 autoimmune hepatitis. No clinical (in particular rheumatological manifestations), biochemical or immunoserological differences were detectable between antibodies against cyclic citrullinated peptide positive and negative type 1 autoimmune hepatitis sera, with the exception of rheumatoid factor, always negative in the positive ones.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Antibodies against cyclic citrullinated peptide can be detected in a subgroup of patients with type 1 autoimmune hepatitis. They might be part of the wide range of autoantibody production characteristic of this condition and\/or, less probably, be predictive of future rheumatoid arthritis development.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02686.x","type":"journal-article","created":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T16:33:53Z","timestamp":1130430833000},"page":"951-955","source":"Crossref","is-referenced-by-count":28,"title":["Anti\u2010cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis"],"prefix":"10.1111","volume":"22","author":[{"given":"M.","family":"FUSCONI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"VANNINI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"DALL'AGLIO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"PAPPAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"CASSANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"BALLARDINI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"FRISONI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"GRASSI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. B.","family":"BIANCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"ZAULI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180435"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250510"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92024-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180102"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80026-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260306"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018880429469"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar395"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20044"},{"key":"e_1_2_6_14_2","first-page":"231","article-title":"Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis","volume":"32","author":"Raza K","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cair.2003.11.001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20355"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1041"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.08.002"},{"key":"e_1_2_6_20_2","first-page":"23","article-title":"Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies","volume":"5","author":"Cassani F","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260305"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.20316","article-title":"Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CPPs) influences the severity of rheumatoid arthritis","volume":"50","author":"Gaalen FA","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.10357"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.4177"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02686.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02686.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:44:06Z","timestamp":1697197446000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02686.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,27]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02686.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02686.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,27]]}}}